First safety outcomes for Rigicon ContiClassic^® artificial urinary sphincter

Author(s): Steven K. Wilson, Eric Chung, Brian Langford, Ricardo Schlesinger, Orhan Koca, Abdulmuttalip Simsek, Cristian Persu, Tobias Pottek, John Mulcahy

JOURNAL

IJIR: Your Sexual Medicine Journal

YEAR

2023

DOI

https://doi.org/10.1038/s41443-023-00748-8

View on Publisher Site

Abstract Short Summary

This study evaluated early safety outcomes of the Rigicon ContiClassic® AUS in 116 patients. Data showed a 6.9% revision rate and 93.2% 12-month device survival.

Abstract

Objective:

To report the first safety outcomes of the Rigicon ContiClassic^® artificial urinary sphincter in the treatment of male stress urinary incontinence.

Key Findings:

The study found a low revision rate of 6.9% with no infections among 116 patients implanted with the ContiClassic^® AUS. The 12-month Kaplan-Meier survival rate was 93.2%. Most revisions were due to iatrogenic errors like incorrect cuff sizing or connector misplacement.

Conclusion:

The early clinical experience with the Rigicon ContiClassic^® AUS shows a favorable safety profile with low complication and revision rates. The device appears comparable in safety to other sphincters on the market.

Clinical Relevance:

The results support the Rigicon ContiClassic^® AUS as a viable alternative to existing artificial urinary sphincters, potentially expanding treatment options for male stress urinary incontinence.

Keywords

ContiClassic artificial urinary sphincter male SUI urinary incontinence AUS revision rate Rigicon continence surgery postoperative outcomes

This publication is available through the external link above. See the abstract for a summary of the research.

Back to Clinical Evidence